Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Down 7.8% in December

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 1,377,300 shares, a drop of 7.8% from the December 15th total of 1,494,600 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 13,773.0 days.

Swedish Orphan Biovitrum AB (publ) Price Performance

Shares of BIOVF stock opened at $28.30 on Friday. The business’s fifty day moving average is $28.47 and its 200 day moving average is $28.40. The company has a quick ratio of 0.49, a current ratio of 0.73 and a debt-to-equity ratio of 0.30. The stock has a market cap of $10.07 billion, a price-to-earnings ratio of 47.97 and a beta of 0.51. Swedish Orphan Biovitrum AB has a twelve month low of $22.87 and a twelve month high of $32.25.

Wall Street Analysts Forecast Growth

Separately, Barclays raised Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research report on Wednesday, January 8th.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.